Bernstein analyst Lee Hambright raised the firm’s price target on Medline (MDLN) to $56 from $49 and keeps an Outperform rating on the shares. The firm cites a strong quarter and an in-line guide. Bernstein believes the company’s growth algorithm offers uniquely strong visibility.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN: